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Abstract
Functional neurogenomics is the interface between neurosciences knowledge and Omics 
sciences data. It characterizes, identifies, and analyzes expression of genes involved 
in the function of several structures of brain and cognition. Its major goal is to under-
stand the main pathways of brain function, plasticity, and the etiopathogenesis of brain 
diseases. We have done an integrate analysis of global brain gene expression linked to 
cognitive disability in Down syndrome. It is a new approach to better understand the 
control of complex brain networks of gene expression involved in this syndrome. The 
objective of the chapter is to present computationally simulate data of global expres-
sion of 108 genes associated with cognitive disability and neuroplasticity from DNA 
microarray experiments of postmortem brain from normal controls and patients with 
Down syndrome. Some genes that were studied are involved in metabolic process and 
also promote hippocampal plasticity; interventions reawaken the neural plasticity may 
permit improved cognition. One of the striking findings was that some of the causes of 
dysregulation appear to result in the brain being trapped in an immature state of synaptic 
development. Understanding the functional neurogenomics of Down syndrome brain, 
emerge a new scenario to partially overcome cognitive disability through new prospec-
tive genomic therapies.
Keywords: brain, functional neurogenomics, omics sciences, Down syndrome, 
neuroplasticity, cognitive disability, data mining, DNA microarrays, computational 
biology
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1. Introduction
Never before in brain research, the development of modern brain imaging technologies and 
the application of new brain analyses by using the Omics sciences, have provided new knowl-
edge to explore not only the biological essence of human intelligence as well as the relation-
ship between brain function and cognition. As results of such studies, actually we have an 
unprecedented state to understand the relationship between brain and intelligence [1]. Brain 
function and its dysfunction throughout life are determined by the interaction of genetic fac-
tors with internal and external environmental events, signals, and stimuli [2]. Most of this 
process occur early in life and exert many effects that persist throughout adulthood. In this 
scenario, the hippocampus is one of the targets that plays a crucial role in learning, memory 
storage and retrieval, and in general cognitive function; the study and management of hip-
pocampal neuronal networks, open the real possibility to induce adaption by increasing its 
function, as a base for a real hippocampal rehabilitation combined therapies [3–5].
This chapter presents the main results of our investigations in the Down syndrome global gene 
expression from an integrative approach of functional neurogenomics (FN) as the interface 
of neurosciences and omics sciences (OS). NF emerges as an integrative research approach 
which applies several methods of computational sciences and OS strategies, to get under-
standing of how their gene-product interacts in complex networks and regulates the brain 
homeostasis. The information derived from the functional neurogenomics approach, could 
serve in the future, to develop new promising therapeutic protocols and genome editing strat-
egies for trustworthy cognitive rehabilitation based on the hippocampal neuroplasticity [6–9].
2. Generalities of Down syndrome
Down syndrome (DS) is the most common aneuploidy in children caused by an extra 21 
chromosome, affecting worldwide 1 in 600 live births and 1 in 150 conceptions [10]; however, 
remarkable differences are registered among countries that depend on sociocultural variables 
[11]. The triplication of genes on HSA21 causes a wide spectrum of neurological phenotypes 
in DS, including intellectual and cognitive disabilities. Patients with DS display not only 
delayed linguistic skills and a variable degrees of cognitive and intellectual disabilities, but 
also behavioral issues such as attention-deficit disorder (ADD, sometimes with hyperactivity) 
and autism spectrum disorder (ASD) [12–16]. The cognitive impairments extend further after 
development, as individuals with DS are more prone to develop Alzheimer’s type dementia 
[17]. In addition, patients with DS are susceptible to epilepsy in the form of infantile spasms 
and tonic-clonic seizures with myoclonus at early ages [16].
It was reported that brain of Down syndrome has a reduction of size and diminishing num-
ber of neuron density. Part of the cognitive dysfunction in DS, lies not only in the progres-
sive neuronal degeneration/cell death and impaired neurogenesis seen in this developmental 
and degenerative disorder, but also in the reduction in dendrite formation and spine density, 
which result in a disruption of synaptic function. These pathological abnormalities in humans 
are, in part, replicated in DS animal models which show defects in learning, social interac-
tions, memory, and seizures [18–22].
Advances in Research on Down Syndrome32
3. Functional neurogenomics: the systemic integration of brain 
global gene expression
The spectacular advances in OS, had led to obtain comprehensive global information regard-
ing the transcriptome of some neurological diseases [23]. In this regard, the use of DNA 
microarrays to study global transcription is widely spread. This methodology has allowed 
performing comprehensive analysis of changes in transcriptional expression of many genes 
associated with the pathophysiology of DS [24]. In addition, previous studies have shown 
the importance of using postmortem brain tissue to analyze the transcriptome of different 
conditions and different regions of the human brain including those individuals with DS [25]. 
The gene expression profile of the central nervous system (CNS) is unique. At least 30–50% 
of approximately 22,000 known protein-coding genes are expressed across all structures of 
the human brain [26]. Moreover, the human brain has the highest level of gene expression 
compared with other mammal species [27]. Neurogenomics research applies genomic strate-
gies to identify and analyze genes that are involved in the function of nervous system. One 
of the main goals is to build a really systemic approach that contributes to explain the brain 
development, function, plasticity, and associated diseases [6, 7, 28, 29].
As shown in Figure 1, the major goal in functional neurogenomics is to analyze the global 
gene expression among different structures of the brain in order to identify the normal regula-
tion of transcription and characterize genes associated with several neurological pathologies 
with cognitive and intellectual disabilities phenotypes [28–31].
The functional neurogenomic analysis starts with planning of global gene expression in brain. 
In this sense, DNA microarray experiments are a powerful experimental tool to study the 
transcriptome profile of brain which varies within specific regions and changes with age and 
with internal and external environmental conditions [32, 33].
DNA microarray experiments generate large amounts of data; for example, in a gene expres-
sion microarray study, 22,000 genes x 100 samples will generate 2.2 million data points. This 
terabyte amount data of information is necessary to be analyzed by computational simulation 
procedures that use bioinformatics analysis tools to get information about the spatial and 
temporal gene expression. Moreover, the bioinformatics analysis permits to extract informa-
tion about genes which are expressed in normal and pathological samples of postmortem 
brains [34, 35].
In addition, genomic experiments are often noisy and are not normally distributed, and usu-
ally contain missing values in the expression matrix. To overcome such problem and to obtain 
biological relevant interpretations of the genome expression data, robust biostatistical analy-
ses are required [36, 37]. In general, statistical analyses of genomic data can be divided into 
two major categories: supervised and unsupervised methods [36]. Supervised analysis is used 
to identify genes that are differentially expressed between groups of samples, as well as to 
find genes that can be used to accurately predict the characteristics of groups. The unsuper-
vised approaches characterize genomic data without prior input or knowledge of predeter-
mined pattern. Unsupervised analysis is used to identify internal structure in the genomic 
data set. The most commonly used unsupervised analysis tool is Hierarchical clustering and 
Principal Components Analysis (PCA) [37].
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The final result of the flow of analytical process previously described, is to correlate the gene 
expression profiles variation within specific regions of the brain to obtain a better knowledge 
about the functional correlations. In this sense, DNA microarray experiments showed that 
the transcriptome profile of the CNS is specific of brain structure and also the signals that 
modulate it [38, 39].
4. Cognitive disability and neuroplasticity: our main approach
Cognition refers to the mental processes that are involved in acquiring knowledge and com-
prehension. These processes include thinking, knowing, remembering, judging, and problem 
solving. All of them are higher level functions of the brain and encompass language, imagi-
nation, perception, and planning [40]. Neuroplasticity is the ability of the nervous system to 
adapt to different environmental conditions and stimuli; it requires a well-conserved and flex-
ible repertoire of molecular mechanisms [41]. Neural plasticity, allows neurons to regenerate 
Figure 1. The experimental and analytical procedures applies in functional neurogenomics. The flow of procedures starts 
with the analysis of global gene expression profiles, using the technology of DNA microarray, which is followed by a 
trend of bioinformatics and statistical analysis of the results of the big data generated by DNA microarray experiments. 
As a result of the integrative analysis, the functional correlation between global gene expression and several interaction 
processes are obtained.
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both anatomically as well as functionally, in a process call neurogenesis; also to form new 
synaptic connections—synaptogenesis, and in some cases of new dendrites generation—den-
dritogenesis [42, 43]. Because neuroplasticity is based on the ability of brain to recover and 
restructure itself, it allows us to consider that its adaptive potential to recover after disor-
ders or injuries, would be a point of departure for developing therapeutic strategies toward 
reducing the effects of altered structures due to cognitive associated pathologies including DS 
among others [44].
The point of departure of our studies lies in the fact that a failure in the crosstalk between cog-
nitive process and neuroplasticity would be a major effector for cognitive disability (CD) in 
DS brain [45–48]. Some genetic mechanisms or even alteration of brain development homeo-
stasis has important neurodevelopmental consequences produced by CD [49].
4.1. Our methodological approach
In order to test our proposal, the initial approach started with a bibliographic search of full 
papers in PubMed of publications reported neuroplasticity and CD in Down syndrome. We 
used the following crossed descriptors to perform that search: DS, neuroplasticity and cogni-
tion and cognitive disability, and genes associated. We filtered six full papers describing genes 
that involved in cognition and neuroplasticity in DS. Information consigned in this article led 
us to pick up 106 genes involved in neuroplasticity and cognitive process such as memory and 
learning. Those genes were the initial background to perform our computational simulations 
and identify their functional roles in several structures of brain cortex. Moreover from gender 
and age gene expression values, we obtain data about their temporal and spatial regulations. 
The list and main characteristics of selected genes are consigned in Supplementary Table 1.
As a source to calculate the values of expression for selected gene, this initial bibliographic 
search was crossed with DNA microarray experiments consigned in the database of GEO 
DataSet of NCBI (https://www.ncbi.nlm.nih.gov/gds/). Combining the descriptors: Down 
syndrome and global transcription and neuroplasticity and cognition and brain, we found 
nine DNA microarray experiments. However, only one of them fitted the statistical signifi-
cance sample size to obtain trustable information about the functional neurogenomics in DS.
We used the log10 transformed expression values of a DNA microarray experiment whose 
registration code and free access in the GEO database was GSE59630 (http://www.ncbi.nlm.
nih.gov/geo/query/acc.cgi?acc=GSE59630), previously deposited by Olmos et al. [50]. The 
microarray experiment selected included gene expression data of 47,000 probes from 58 DS 
patients (25 females and 33 males) and 58 healthy controls (25 females and 33 males) of post-
mortem brain samples classified by gender and age, and in 11 structures of cerebral cortex.
4.2. Functional analysis
Free use Cytoscape 3.2 open software platform was used for visualizing and analyzing the 
genetic interaction networks among the selected human genes associated with cognition 
and neuroplasticity processes. Biological Networks Gene Ontology v2.6 plugin (BiNGO 
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ID Gen symbol Name Locus Function—gene ontology (GO)
90 ACVR1 Activin A receptor type 1 2q24.1 ATP binding
9509 ADAMTS2 ADAM metallopeptidase with 
thrombospondin type 1 motif 2
5q35.3 Metalloendopeptidase  
activity, metallopeptidase  
activity
9370 ADIPOQ Adiponectin 3q27.3 Cytokine activity, hormone 
activity
152 ADRA2C Adrenoceptor alpha 2C 4p16.3 Alpha-2A adrenergic receptor 
binding, epinephrine binding
8906 AP1G2 Adaptor related protein complex 1 
gamma 2 subunit
14q11.2 Protein transporter activity
361 AQP4 Aquaporin 4 18q11.2 Protein binding
10317 B3GALT5 Beta-1,3-galactosyltransferase 5 21q22.2 Protein glycosylation
25825 BACE2 Beta-site APP-cleaving enzyme 2 21q22.2–q22.3 Amyloid-beta metabolic process
627 BDNF Brain-derived neurotrophic factor 11p14.1 Neurotrophin TRKB receptor 
binding
666 BOK BCL2 family apoptosis regulator 2q37.3 BH domain binding
54014 BRWD1 Bromodomain and WD repeat 
domain containing 1
21q22.2 Cytoskeleton organization
55969 C20orf24 Chromosome 20 open reading 
frame 24
20q11.23 Olfactory receptor activity
114041 B3GALT5-AS1 B3GALT5 antisense RNA 1 21q22.2 Putative uncharacterized
721 C4B Complement C4B 6p21.33 Carbohydrate binding, 
endopeptidase inhibitor activity
23562 CLDN14 Claudin 14 21q22.13 Protein complex assembly
54102 CLIC6 Chloride intracellular channel 6 21q22.12 NOT glutathione metabolic 
process
1277 COL1A1 Collagen type I alpha 1 chain 17q21.33 Protease binding, extracellular 
matrix structural  
constituent, protein binding
1278 COL1A2 Collagen type I alpha 2 chain 7q21.3 SMAD binding, identical protein 
binding
1476 CSTB Cystatin B 21q22.3 Adult locomotory behavior
7852 CXCR4 C-X-C motif chemokine receptor 4 2q22.1 C-C chemokine binding
51523 CXXC5 CXXC finger protein 5 5q31.2 Sequence-specific DNA binding, 
signal transducer activity, 
transcription  
factor binding
147991 DPY19L3 DPY-19-like 3 19q13.11 Mannosyltransferase activity, 
transferase activity
1812 DRD1 Dopamine receptor D1 5q35.2 Dopamine binding
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ID Gen symbol Name Locus Function—gene ontology (GO)
3920 DSCAM DS cell adhesion molecule 21q22.2 Nervous system development, 
Locomotory behavior, dendrite 
morphogenesis
10311 DSCR3 DSCR3 arrestin fold containing 21q22.13 Intracellular protein transport
53820 DSCR6 Ripply transcriptional repressor 3 21q22.13 Negative regulation of cell 
proliferation
84677 DSCR8 Down syndrome critical region 8 
(non-protein coding)
21q22.13 Biological_process
1846 DUSP4 Dual specificity phosphatase 4 8p12 MAP kinase serine/threonine 
phosphatase activity
1859 DYRK1A Dual specificity tyrosine 
phosphorylation regulated kinase 
1A
21q22.13 Circadian rhythm
1958 EGR1 Early growth response 1 5q31.2 RNA polymerase II regulatory 
region sequence-specific DNA 
binding
2078 ERG ERG, ETS transcription factor 21q22.2 Cell proliferation
2114 ETS2 ETS proto-oncogene 2, transcription 
factor
21q22.2 Skeletal system development
2199 FBLN2 Fibulin 2 3p25.1 Extracellular matrix binding, 
calcium ion binding
252995 FNDC5 Fibronectin type III domain 
containing 5
1p35.1 Hormone activity, 
molecular_function
2487 FRZB Frizzled-related protein 2q32.1 Wnt-activated receptor activity, G 
protein-coupled receptor activity
2670 GFAP Glial fibrillary acidic protein 17q21.31 Structural constituent of 
cytoskeleton, protein binding
2719 GPC3 Glypican 3 Xq26.2 Heparan sulfate proteoglycan 
binding, peptidyl-dipeptidase 
inhibitor activity
10457 GPNMB Glycoprotein nmb 7p15.3 Integrin binding, heparin binding, 
chemoattractant activity
3141 HLCS Holocarboxylase synthetase 21q22.13 Enzyme binding
3150 HMGN1 High mobility group nucleosomal 
binding domain 1
21q22.2 Transcription-coupled nucleotide-
excision repair
9456 HOMER1 Homer scaffolding protein 1 5q14.1 G protein-coupled glutamate 
receptor binding
9454 HOMER3 Homer scaffolding protein 3 19p13.11 G protein-coupled glutamate 
receptor binding
3479 IGF1 Insulin-like growth factor 1 12q23.2 Growth factor activity, hormone 
activity, insulin-like growth factor 
receptor binding, insulin-like 
growth factor receptor binding
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ID Gen symbol Name Locus Function—gene ontology (GO)
3488 IGFBP5 Insulin-like growth factor binding 
protein 5
2q35 Fibronectin binding, protein 
binding
3489 IGFBP6 Insulin-like growth factor binding 
protein 6
12q13.13 Growth factor binding, receptor 
binding
3600 IL15 Interleukin 15 4q31.21 Cytokine activity, cytokine 
receptor binding
3623 INHA Inhibin alpha subunit 2q35 Cytokine activity, growth factor 
activity
3708 ITPR1 Inositol 1,4,5-trisphosphate receptor 
1
3p26.1 Calcium channel inhibitor activity
170850 KCNG3 Potassium voltage-gated channel 
modifier subfamily G member 3
2p21 Delayed rectifier potassium 
channel activity
3772 KCNJ15 Potassium voltage-gated channel 
subfamily J member 15
21q22.13-q22.2 Potassium ion import
3775 KCNK1 Potassium two pore domain 
channel subfamily K member 1
1q42.2 Inward rectifier potassium 
channel activity
57576 KIF17 Kinesin family member 17 1p36.12 Microtubule motor activity, ATP 
binding, microtubule binding,
7071 KLF10 Kruppel-like factor 10 8q22.3 RNA polymerase II core promoter 
proximal region sequence-specific 
DNA binding
11202 KLK8 Kallikrein related-peptidase 8 19q13.41 Serine-type endopeptidase 
activity
150082 LCA5L LCA5L, lebercilin like 21q22.2 Protein binding
9663 LPIN2 Lipin 2 18p11.31 Phosphatidate phosphatase 
activity
4058 LTK Leukocyte receptor tyrosine kinase 15q15.1 ATP binding, protein binding
4147 MATN2 Matrilin 2 8q22.1-q22.2 Calcium ion binding
4239 MFAP4 Microfibril associated protein 4 17p11.2 Protein binding
283078 MKX Mohawk homeobox 10p12.1 Sequence-specific DNA binding
25902 MTHFD1L Methylenetetrahydrofolate 
dehydrogenase (NADP+ 
dependent) 1 like
6q25.1 Formate-tetrahydrofolate 
ligase activity, 
methylenetetrahydrofolate 
dehydrogenase (NADP+) activity
1463 NCAN Neurocan 19p13.11 Calcium ion binding
4885 NPTX2 Neuronal pentraxin 2 7q22.1 Carbohydrate binding
51299 NRN1 Neuritin 1 6p25.1 C-terminal protein lipidation
51559 NT5DC3 5′-Nucleotidase domain containing 
3
12q23.3 Metal ion binding
4908 NTF3 Neurotrophin 3 12p13.31 Chemoattractant activity, 
neurotrophin p75 receptor 
binding
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ID Gen symbol Name Locus Function—gene ontology (GO)
64881 PCDH20 Protocadherin 20 13q21.2 RNA binding, calcium ion 
binding
5121 PCP4 Purkinje cell protein 4 21q22.2 Positive regulation of neuron 
differentiation
5179 PENK Proenkephalin 8q12.1 Neuropeptide hormone activity
51227 PIGP Phosphatidylinositol glycan anchor 
biosynthesis class P
21q22.13 Preassembly of GPI anchor in ER 
membrane
130271 PLEKHH2 Pleckstrin homology, MyTH4 and 
FERM domain containing H2
2p21 Actin binding, identical protein 
binding
57460 PPM1H Protein phosphatase, Mg2+/Mn2+ 
dependent 1H
12q14.1-q14.2 Phosphoprotein phosphatase 
activity, protein serine/threonine 
phosphatase activity
3275 PRMT2 Protein arginine methyltransferase 2 21q22.3 Developmental cell growth
8624 PSMG1 Proteasome assembly chaperone 1 21q22.2 Proteasome assembly
754 PTTG1IP PTTG1 interacting protein 21q22.3 Protein import into nucleus
51655 RASD1 RAS related dexamethasone 
induced 1
17p11.2 GTPase activity, GTP binding
10633 RASL10A RAS like family 10 member A 22q12.2 Signal transduction, small GTPase 
mediated signal transduction
1827 RCAN1 Regulator of calcineurin 1 21q22.12 Central nervous system 
development
5997 RGS2 Regulator of G protein signaling 2 1q31.2 G-protein alpha-subunit binding
85397 RGS8 Regulator of G protein signaling 8 1q25.3 GTPase activator activity
56475 RPRM Reprimo, TP53 dependent G2 arrest 
mediator homolog
2q23.3 Protein binding
861 RUNX1 Runt related transcription factor 1 21q22.12 Peripheral nervous system neuron 
development
347735 SERINC2 Serine incorporator 2 1p35.2 L-serine transmembrane 
transporter activity
5271 SERPINB8 Serpin family B member 8 18q22.1 Serine-type endopeptidase 
inhibitor activity
6450 SH3BGR SH3 domain binding glutamate rich 
protein
21q22.2 Positive regulation of signal 
transduction
6470 SHMT1 Serine hydroxymethyltransferase 1 17p11.2 L-allo-threonine aldolase activity, 
glycine hydroxymethyltransferase 
activity
6493 SIM2 Single-minded family bHLH 
transcription factor 2
21q22.13 Embryonic pattern specification
6574 SLC20A1 Solute carrier family 20 member 1 2q14.1 High-affinity inorganic 
phosphate:sodium symporter 
activity
65012 SLC26A10 Solute carrier family 26 member 10 12q13.3 Anion:anion antiporter activity
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tool) was used to search which gene ontology (GO) categories are significantly overrepre-
sented in a set of genes. A hypergeometric test was applied to determine which categories 
were significantly represented (P-value < 0.05); significant values were adjusted for multiple 
hypotheses testing using the Bonferroni family wise error rate correction [51]. From net-
work analyzer plugin of the Max Planck Institute Informatik, network topology parameters 
were calculated.
ID Gen symbol Name Locus Function—gene ontology (GO)
57709 SLC7A14 Solute carrier family 7 member 14 3q26.2 Amino acid transmembrane 
transporter activity
114826 SMYD4 SET and MYND domain containing
4
17p13.3 Metal ion binding, 
methyltransferase activity
6651 SON SON DNA binding protein 21q22.11 Negative regulation of apoptotic 
process
6664 SOX11 SRY-box 11 2p25.2 RNA polymerase II core promoter 
sequence-specific DNA binding
8869 ST3GAL5 ST3 beta-galactoside alpha-2,3-
sialyltransferase 5
2p11.2 Beta-galactoside (CMP) alpha-2,3-
sialyltransferase activity
27090 ST6GALNAC4 ST6 N-acetylgalactosaminide alpha-
2,6-sialyltransferase 4
9q34.11 Alpha-N-acetylgalactosaminide 
alpha-2,6-sialyltransferase activity
7058 THBS2 Thrombospondin 2 6q27 Heparin binding, protein binding
7059 THBS3 Thrombospondin 3 1q22 Heparin binding, calcium ion 
binding
7074 TIAM1 T-cell lymphoma invasion and 
metastasis 1
21q22.11 Neuron projection extension
757 TMEM50B Transmembrane protein 50B 21q22.11 Biological_process
7109 TRAPPC10 Trafficking protein particle complex 
10
21q22.3 Early endosome to Golgi transport
10098 TSPAN5 Tetraspanin 5 4q23 Enzyme binding
7267 TTC3 Tetratricopeptide repeat domain 3 21q22.13 Protein K48-linked ubiquitination
84959 UBASH3B Ubiquitin associated and SH3 
domain containing B
11q24.1 Identical protein binding, 
phosphoprotein binding
221044 UCMA Upper zone of growth plate and 
cartilage matrix associated
10p13 Negative regulation of osteoblast 
differentiation
7422 VEGFA Vascular endothelial growth factor 
A
6p21.1 Chemoattractant activity, cytokine 
activity
7485 WRB Tryptophan rich basic protein 21q22.2 Tail-anchored membrane protein 
insertion into ER membrane
Table 1. Description of genes associated with neuroplasticity and cognition. Information taken from the NCBI—Genbank 
platform (Supplementary table).
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4.3. Z-score transformation
The raw intensity data for each gene in the DNA microarray experiment was log10 trans-
formed and then used for the calculation of Z score [52]. Z scores were calculated by subtract-
ing the mean log gene intensities (within a single experiment) from the log intensity data for 
each gene, and dividing that result by the SD of all measured log intensities, according to the 
Z-score transformation (1):
  Z − score =   (Log intensity of G − mean log intensity G…Gn)     _______________________________________________________ 
Standard deviation log G…Gn (1)
All Z-score values were normalized on a linear scale −3.0 < 0 > +3.0. In this, the corresponding 
gene is overexpressed if the value of Z-score is greater than zero; on the contrary, it is under-
expressed, if its value is negative.
4.4. Multivariate statistical analysis
Nonparametric analyses for comparing median values of Z-score were performed among 
gender and age variables between DS patients and healthy control. Wilcoxon signed-rank test 
was used to calculate differences between medians of two samples.
Data of Z-score values of samples from DS and controls were compared to establish signifi-
cant difference in gender in DS and controls and by age ranks since 16 weeks of gestation to 
6 months; since 7 months up to 1 year; 2–3 years; 10–19 years; and 22 years and older groups. 
Moreover, Z-scores for the genes included in the study, were compared between DS and con-
trol samples in 11 structures of brain cortex including: dorsolateral prefrontal cortex (DFC), 
visual cortex (V1C), cerebellar cortex (CBC), orbitofrontal cortex (OFC), ventral frontal cor-
tex (VFC), inferior temporal cortex (ITC), hippocampus (HIP), medial frontal cortex (MFC), 
somatosensory cortex (S1C), inferior parietal cortex (IPC), and superior temporal cortex (STC). 
To perform the HCA, Euclidean distance was used as a measure of distance between DS and 
control samples of Z-score values in several structures of brain cortex; p < 0.05 was defined as 
a threshold [53].
5. Our results
5.1. Protein network and gene interactions
A total of 3135 protein interactions among genes associated with cognition and neuroplasti-
city process expressed in brains of DS subjects were recorded (Figure 2A and B). The central 
proteins of the main node of the network corresponded to RUNX1 (runt related transcrip-
tion factor 1) at 21q22.12; SON (SON DNA binding protein) at 21q22.11; RGS2 (regulator 
of G protein signaling 2) at 1q31.2; UBASH3B (ubiquitin associated and SH3 domain con-
taining B) at 11q24.1; DYRK1A (dual specificity tyrosine phosphorylation regulated kinase 
1A) at 21q22.13; GFAP (glial fibrillary acidic protein) at 17q21.31; TIAM1 (T-cell lymphoma 
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invasion and metastasis 1) at 21q22.11; and THBS3 (thrombospondin-3) at 1q22. The most 
important topological parameters of the network were: clustering coefficient with a value 
of 0.33; average number of neighbors 2367; network density 0.001 and 12 connected com-
ponents (Table 2).
From GeneMANIA Cytoscape plugin, we identified the top five functions of that genes. They 
corresponded to regulation of behavior, behavior, muscle cell migration, hormone activity, 
and G coupled glutamate receptor.
5.2. Differential gene expression in post-mortem brains of DS patients
Overall no statistical differences between the median values in Z-score of the 108 gene in con-
trols and DS patients were recorded (Controls 0.2869 vs. DS 0.3318; Wilcoxon rank test p > 0.05). 
However, significant differences in the medians of Z-score in some genes were determined. 
Thus, in the DS brains, the overexpression levels corresponded to genes CXXC5 (Controls 
−1.2376 vs. DS 0.7492), EGR1 (controls −1.2266 vs. DS 0.5442), and NCAN (controls −1.2901 vs. 
DS 0.5440).
The main GO categories of brains processes associated with DS involved in its etiopathogene-
sis included: respiratory electron transport chain (3.31E − 41), positive regulation of cell death 
(1.17E − 39), positive regulation of release of cytochrome c from mitochondria (9.19E − 37), 
negative regulation of cell motility involved in cerebral cortex radial glia guided migration 
Figure 2. Protein-protein interaction (PPI) networks of genes associated with cognition and neuroplasticity constructed 
from data experiments of DNA microarray of genes expressed in Down syndrome postmortem brain samples. Data 
of log2 intensity values were obtained from DNA microarray experiment by Olmos-Serrano et al. [50], (GEO Dataset 
accession GSE59630). (A) Full network of 108 genes associated with cognition and neuroplasticity; (B) sub-network 
showing five of the major nodes found in the original network; Cytoscape 3.2 program was used to generate the graphical 
representation of built networks; UBASH3B, ubiquitin associated and SH3 domain containing B; SON, SON DNA 
binding protein; G0S8 (RGS2), regulator of G protein signaling 2; DYRK1A, dual specificity tyrosine phosphorylation 
regulated kinase 1A; RUNX1, runt-related transcription factor 1.
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(5.20E − 35), telomere maintenance (1.16E − 34), negative regulation of angiogenesis (4.11E − 
32), and axonogenesis (1.40E − 31) (Table 3). Moreover, focal adhesion (P-value 7.69E − 23) 
and neurotrophin signaling pathway (P-value 3.62E − 19) were also important pathways asso-
ciated with cognitive and neuroplasticity process in brains of DS individuals.
5.3. Evaluation of gene expression by sex and age variables
We observed differential brain expression in 72 genes associated with CD among women 
and men. Medians of brain gene expression in men patients with DS were higher than in DS 
women (p < 0.005 Kruskal-Wallis test) (Figure 4A). Such difference were statically significant 
for the expression of DMXL2 (Z-score of men 1.33 vs. −1.75 in women); CAMTA1 (Z-score of 
men 1.16 vs. −1.73 in women); HCN1 (Z-score of 1.05 vs. −1.73 in women); and ATL1 (Z-score 
of men 0.85 vs. −1.73 in women). On the contrary, we recorded non-significant differences by 
gender in medians values of genes associated with neuroplasticity in brains of DS.
Global gene expression among the different ranks of age in DS brains was variable and depen-
dent of the type of gene. However, slight differences of expression in brain genes associated 
with neuroplasticity process of Down syndrome and its age dependency were recorded in 
samples of DS brains in comparison with that of normal controls in age ranks since 16 weeks 
of gestation to more than 22 years old. It is noteworthy that DYRK1A, NCAM AND TSPN5 
genes were under-expressed in prenatal brains (Figure 3A–G).
Topological parameter Value
Clustering coefficient 0.33
Connected components 12
Network diameter 12
Network radius 1
Network centralization 0.056
Shortest paths 3.454.424 (93%)
Characteristics path length 5.340
Avg. number of neighbors 2.367
Number of nodes 1919
Network density 0.001
Network heterogeneity 3.105
Isolated nodes 0
Number of self-loops 25
Multi-edge node pairs 595
Table 2. Values of the main topological parameters of the protein interaction network including 106 genes associated 
with cognitive and neuroplasticity process in brain of DS patients.
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5.4. Gene expression in cerebral cortex
Some of the most differentially expressed genes across the cerebral cortex are shown in 
Figure 4A–H. In particular, expression in S1C showed significant differences for SERPIB8 
(Control 0.2288 vs. DS −2.0288), SHMT1 (control 0.1542 vs. DS −2.1269) and THBSH3 (control 
Figure 3. Differential values of median Z-score by age rank for six principal genes associated with cognitive disability 
and neuroplasticity expressed in brain samples of Down syndrome. (1) 16 Weeks of gestation to 6 months; (2) 7 months 
to 1 year; (3) 2–3 years; (4) 8–18 years; and (5) over 22 years of age. Y-axis values are the median of Z-score.
GO_ID Process P-value*
9987 Respiratory electron transport chain 3.31E – 41
48522 Positive regulation of cell death 1.17E − 39
48518 Positive regulation of release of cytochrome c from mitochondria 9.19E − 37
48523 Negative regulation of cell motility involved in cerebral cortex radial glia guided 
migration
5.20E − 35
44260 Telomere maintenance 1.16E − 34
48519 Negative regulation of angiogénesis 4.11E − 32
16043 Axonogenesis 1.40E − 31
43170 Glycoprotein biosynthetic process 3.33E − 30
10604 Positive regulation of telomerase activity 1.82E − 29
9893 Positive regulation of protein processing in phagocytic vesicle 5.01E – 28
*P-values were calculated using the correction of Bonferroni.
Ontology v2.6 plugin (BiNGO tool) was used to search gene ontology (GO) categories.
Table 3. The top 10 GO categories of brains processes associated with DS involved in its etiopathogenesis.
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0.1542 vs. −2.0709) genes. In hippocampus, we recorded differential expression for EGR1 
(control 0.8084 vs. DS −1.4648), SMYD4 (control 0.3946 vs. −1.8171), PCDH20 (control 0.7462 
vs. DS −1.3194), DYRK1A (control 1.4284 vs. DS −1.7390), and VEGFA (control 0.6648 vs. DS 
−1.3280). In S1C, the most under expressed genes in Down syndrome were MFAP4 (control 
0.1711 vs. DS −2.1461), BDNF (control 0.2136 vs. DS −2.1039), RGS8 (control 0.4013 vs. DS 
−1.9024), and SERINC2 (control 0.2584 vs. DS −1.8843). Finally in V1C, ADIPOQ (control 
−0.0035 vs. DS −2.1880), and TSPAN5 (control 0.7392 vs. DS −1.3315) were the most under-
expressed genes in DS samples.
6. Discussion
In general, our results provided strong evidence to propose that in brains of DS, a fail in the 
cross talk of global expression between genes associated with cognition and neuroplasticity 
process (most of them located out of chromosome 21), is complex and is associated not only 
with pathological profiles but with gender, age, and is also dependent of the brain cortex 
structures. However, according with the functional roles, differential expression of particular 
groups of genes would cause a considerable impact on the metabolic pathways, in which they 
participate and are directly or indirectly involved in the regulation of molecular events associ-
ated with cognition and neuroplasticity in brain of patients with DS.
Overall, this study also support the hypothesis of a systemic imbalance of brain protein 
homeostasis, or proteostasis network as an important effect of trisomy not only in loci of 
Figure 4. Differential gene expression in different structures of brain cortex of genes associated with cognitive disability 
and neuroplasticity in DS samples of brain. DFC, dorso lateral prefrontal cortex; V1C, visual cortex; CBC, cerebellar 
cortex; OFC, orbito frontal cortex; VFC, ventral frontal cortex; ITC, inferior temporal cortex; HIP, hippocampus; MFC, 
medial frontal; S1C, cortex somatosensory cortex; IPC, inferior parietal cortex and STC, superior temporal cortex. Y-axis 
values are the median of Z-score.
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chromosome 21 but also in genes located in other chromosomes [54]. Together our results 
and others collectively suggest that disturbance in the proteostasis network of cognitive and 
neuroplasticity process, could contribute to the accumulation of protein aggregates, such 
as amyloid deposits and NFTs, which occur very early in DS. It is likely that a sub-optimal 
functioning of degradative systems occur in DS neurons, which in turn provide the basis for 
further accumulation of toxic protein aggregates which have an indirect impact on the neuro-
plastic process in several structures of brain cortex [55, 56].
According to our results and with the information reviewed in literature, V-CAM1, SPTAN1, 
DYNC1H1, PAFAH1B1, H3F3A, ACVR1, THBS3, and TSPAN5 were the proteins with the 
highest number of protein interactions. All of them directly or even indirectly regulate sev-
eral brain processes associated with cognition and neuroplasticity [57, 58]. In this sense, it is 
relevant to get more knowledge about the implication in those neurophysiological processes 
whose function is altered by either overexpression or by disruption in the network functional 
interaction architecture in DS brains.
For the first time, we obtain strong evidence that brain of male DS had, in general, a higher 
gene expression of cognitive and neuroplasticity process in comparison with that of females. 
The outstanding differences were specifically for DMXL2 (RKPM = 8.02 ± 1.61), CAMTA1 
(RKPM = 4977 ± 1.246), HCN1 (RKPM = 4.88 ± 2.29), and ATL1 (RKPM = 34.764 ± 11.66) genes, all 
of them highly expressed in human brain. Previous evidence indicates that male-biased genes 
are highly enriched for genes involved in neurological and psychiatric disorders such as schizo-
phrenia, bipolar disorder, Alzheimer’s disease, and autism, while no such pattern was seen for 
the female-biased genes, suggesting that the differences in brain disorder susceptibility between 
males and females are likely rooted from the sex-biased gene expression regulation during brain 
development [59]. Moreover, it was previously reported that the excess of male cases with Down 
syndrome is not restricted to free trisomy 21 alone, but appears in translocation cases [60] and 
with the life expectancy found in males with DS, which is significantly greater in females [61]. 
Collectively, our and others analyses reveal the important role of sex-biased genes in brain devel-
opment and neurodevelopmental disorders including the effects in cognitive disability in DS.
DYRK1A, BDNF, PENK, and DRD1 genes are strongly under-expressed in dorsolateral pre-
frontal cortex, hippocampus, orbitofrontal cortex, and ventral frontal cortex in subjects with 
DS in contrast with non-trisomic. Prefrontal cortex is implicated in planning complex cogni-
tive behavior, personality expression, decision-making, and moderating social behavior [62], 
and also plays key roles in cell proliferation and survival, neuronal differentiation, synaptic 
plasticity, and neurodegeneration (for review, see [63, 64]). Supporting our proposal, it has 
been reported that DYRK1A/RCAN1 and NFAT lead to neurodevelopmental alterations that 
might have an impact not only in the brain size and neuronal density, but also in the altered 
common features found in patients with DS [65]. Additionally, a reduction of vesicular GABA 
transporter punctate specifically on parvalbumin-positive interneurons was identified [66, 67]. 
Overall, our results and others suggest that dysfunction of cortical fast-spiking interneurons 
might be central to the pathophysiology of DS.
The under-expression of key genes for brain function correlates with previous reports that 
showed that DS brains are smaller than normal brains and they exhibit neuronal deficits in 
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several regions, including the cerebral cortex structures [68]. Moreover, infants with DS also 
present hypocellularity in this brain structure [69, 70], indicating that defects in prenatal 
development are a major determinant of the deficit in adults. Indeed, fewer cells and disorga-
nized laminas are evident in the cerebral cortex of DS fetuses from as early as the second tri-
mester of gestation [71, 72]. Altogether, the different lines of evidence support the hypothesis 
that DS brain is severely affected by the disturbance of proteostatic network, which is major 
responsible for the cerebral phenotype of DS.
Differential gene expression in hippocampus visual cortex, and somatosensory cortex of 
DYRK1A (dual specificity tyrosine-phosphorylation-regulated kinase 1A), TSPAN5 (tet-
raspanin 5), DRD1 (dopamine receptor D1), EGR1 (early growth response 1), GFAP (glial 
fibrillary acidic protein), and PENK (proenkephalin), which encode proteins that play 
important roles in several brain processes of cognition, learning and the maintenance of 
homeostasis, lead us to proposed them as functional potential predictors to follow up the 
homeostatic imbalance in DS brain.
Finally, this study showed that the integration of knowledge and use of cross talk between 
neurotranscriptomics and bioinformatics is a powerful work to develop transdisciplinary 
and systems biology studies to deal with many insight still remains to be solve in Down 
syndrome. We recommend continuing to study much deeper the complexity of interaction 
networks in the DS etiopathogenesis and brain homeostasis. On the other hand, our approach 
could serve as a starting point for the implementation of strategies to the management of 
cognitive and mental disabilities based on functional neurogenomics and the hippocampal 
neuroplasticity.
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